Speaker illustration

Mrs Elin Rosendahl

Gothenburg (Sweden)

Member of:

European Society of Cardiology

Team and project manager with more than 20 years’ experience of managing global biopharmaceutical development programs and leading cross-functional teams in both large pharma and small biotech companies. Solid experience of all phases of clinical drug development with focus on design of innovative and patient-focused paths to market and effective management of global, cross-functional teams.

Investigation of the effect of the angiotensin II type 2 receptor (AT2R) agonist C21 on plasma NT-proBNP, a diagnostic biomarker, in subjects hospitalised with COVID-19

Event: ESC Congress 2022

Topic: Biomarkers

Session: Cardiovascular aspects of COVID and long-COVID

Thumbnail

This platform is supported by

logo Novo Nordisk